PMID: 8951676Jan 1, 1996Paper

Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
N A SharifJ M Yanni

Abstract

AL-4943A (Olopatadine) is a new antihistaminic and anti-allergic drug. It was tested for its ability to compete for [3H]pyrilamine, [3H]tiotidine and [3H]N-methyl histamine binding to H1, H2 and H3 histamine receptors, respectively. AL-4943A exhibited the highest affinity (Ki = 41.1 +/- 6.0 nM) for H1-receptors and a significantly lower affinity for H2- (Ki = 43,437 +/- 6,257 nM) and H3-receptors (Ki = 171,666 +/- 6,774 nM), respectively. These data showed AL-4943A to be an H1-selective compound, being 1,059- and 4,177-times more selective for H1- than H2- and H3-receptors. AL-4943A was more H1-selective than levocabastine, ketotifen, antazoline and pheniramine and, also, exhibited a low affinity for 38 nonhistamine receptor binding sites. AL-4943A antagonized histamine-induced phosphoinositide (PI) turnover in cultured human conjunctival epithelial cells (IC50 = 9.5 +/- 1.5 nM, n = 3), human corneal fibroblasts (IC50 = 19 nM) and transformed human trabecular meshwork cells (IC50 = 39.9 nM). These data have shown AL-4943A to be a high affinity, high potency H1-selective histamine antagonist. This information, coupled with a long duration of action in an in vivo model of allergic conjunctivitis, suggests that AL-4943A may be a u...Continue Reading

Citations

Jun 4, 2004·Current Allergy and Asthma Reports·Leonard BieloryStephen Bigelson
Sep 14, 2012·Current Allergy and Asthma Reports·Peter K Smith, Bernd Nilius
May 25, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Duraisamy KempurajTheoharis C Theoharides
Jun 1, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·E B CookF M Graziano
Jan 20, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·J M YanniN A Sharif
Jan 5, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·M R HellbergP W Zinke
May 15, 2013·The World Allergy Organization Journal·Daniel C WilliamsPeter K Smith
May 1, 2006·Expert Review of Clinical Immunology·Steven J Lichtenstein, Mark B Abelson
Apr 25, 2008·Expert Opinion on Drug Metabolism & Toxicology·Mark B Abelson, Paul J Gomes
Jun 30, 2009·Expert Opinion on Pharmacotherapy·Hiroyuki Murota, Ichiro Katayama
Feb 20, 2008·Immunology and Allergy Clinics of North America·Leonard Bielory
Feb 20, 2008·Immunology and Allergy Clinics of North America·Leonard Bielory, Mitchell H Friedlaender
Jul 5, 2005·Expert Opinion on Investigational Drugs·M Hingorani
Dec 12, 2000·The Journal of Allergy and Clinical Immunology·L Bielory
Feb 13, 2003·Current Opinion in Allergy and Clinical Immunology·Leonard BieloryTheoharis Theoharides
Jan 16, 2016·Therapeutic Advances in Chronic Disease·Stacey AckermanPaulo J Gomes
Jun 6, 2002·Japanese Journal of Pharmacology·Kenji OhmoriAkimichi Mukouyama
Aug 9, 2011·American Journal of Rhinology & Allergy·Peter K Smith, Joel Collins
Nov 14, 2006·Eye & Contact Lens·Arturo L VillarealStephen C Pflugfelder
Apr 26, 2005·International Ophthalmology·James I McGill
Sep 20, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masakazu WatanabeKaiko Itoh
May 9, 2002·Expert Opinion on Pharmacotherapy·Leonard Bielory
Mar 24, 2010·Expert Opinion on Pharmacotherapy·Andrea Leonardi, Luigi Quintieri
Jun 19, 2015·Pharmacological Reviews·Pertti PanulaHelmut L Haas
Apr 7, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Cemal Çavdarli, Pınar Topcu Yilmaz
Aug 14, 2021·Current Opinion in Allergy and Clinical Immunology·Patrick JaneczkoLeonard Bielory

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.